TScan Therapeutics (TCRX) Projected to Release Quarterly Earnings on Tuesday

TScan Therapeutics (NASDAQ:TCRX) is projected to issue its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect TScan Therapeutics to post earnings of ($0.29) per share and revenue of $1.8750 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 9:30 AM ET.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, hitting the consensus estimate of ($0.22). The firm had revenue of $0.98 million for the quarter, compared to the consensus estimate of $2.50 million. TScan Therapeutics had a negative return on equity of 91.94% and a negative net margin of 1,360.61%. On average, analysts expect TScan Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TScan Therapeutics Trading Up 1.2%

TCRX stock traded up $0.01 during midday trading on Tuesday, hitting $0.73. The stock had a trading volume of 477,452 shares, compared to its average volume of 718,603. The business has a fifty day moving average price of $0.95 and a two-hundred day moving average price of $1.04. TScan Therapeutics has a 1-year low of $0.72 and a 1-year high of $2.57. The firm has a market cap of $47.84 million, a P/E ratio of -0.76 and a beta of 1.06. The company has a current ratio of 6.65, a quick ratio of 6.65 and a debt-to-equity ratio of 0.34.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Wedbush reissued an “outperform” rating and issued a $5.00 price target on shares of TScan Therapeutics in a research note on Tuesday, June 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Friday, July 17th. Wall Street Zen lowered shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $6.00 target price on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $6.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. grew its stake in TScan Therapeutics by 6.0% in the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after acquiring an additional 9,676 shares during the period. JPMorgan Chase & Co. increased its stake in TScan Therapeutics by 8.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company’s stock valued at $417,000 after purchasing an additional 22,642 shares in the last quarter. Marshall Wace LLP bought a new stake in TScan Therapeutics during the 2nd quarter valued at $78,000. Qube Research & Technologies Ltd acquired a new position in TScan Therapeutics during the second quarter worth $99,000. Finally, Jane Street Group LLC acquired a new position in TScan Therapeutics during the second quarter worth $309,000. Institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.